RNA Clinical Trials Solutions

  1. Clinical And Regulatory Strategy 11/7/2023

    Many biotechnology companies come to Australia to conduct early phase clinical trials and take advantage of straightforward regulatory streams and of the lucrative 43.5% R&D cash refund scheme. Biotechnology companies then often look at locations in Asia, such as South Korea, Thailand and China to tap into their huge treatment-naïve patient populations for their later phase clinical research.

  2. Virtual Clinical Trials 6/27/2023

    Learn how virtual clinical trials can offer patient retention and cost benefits compared to traditional trials.

  3. Toxicology Support: Regulatory Strategy And Submission Support 12/2/2025

    Eliminate delays and ensure seamless regulatory alignment with an experienced toxicology services team.

  4. Oncology CRO Services 11/7/2023

    Biotechnology companies are facing increased challenges around participant recruitment and retention, lengthy timeframes and relatively high costs.

  5. Site Management Organization 11/7/2023

    Discover the power of clinical excellence with Acrostar's SMO Division, a dedicated entity operating as part of Novotech.

  6. Patient Recruitment And Site Selection 12/20/2022

    Novotech relies on years of experience, in-country knowledge, and real-life big data to identify and propose the best-performing sites. Uncover the possibilities for your next study.

  7. Early Phase Trials In Australia 9/6/2024

    Australia is a preferred destination for early phase trials because of simple and fast regulatory stream and lucrative R&D cash refund scheme.

  8. New Next-Generation GMP Facility 5/16/2023

    A new state-of-the-art GMP facility has been created to accelerate the development of CRISPR-based cell and gene therapies, overcoming challenges such as procuring reliable GMP-grade sgRNA persist.

  9. Pharmacometric Services 6/27/2023

    Our talented and experienced team can assist in all Clinical Study Phases (Phase 0, I, II and III) and in study designs ranging from First in Human (FIH), Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Drug-Drug Interaction (DDI), Bioavailability/Bioequivalence (BA/BE), Food Effect as well as Special Population studies.

  10. The Future Of Reimbursement For Cell & Gene Therapies 7/27/2022

    Our team excels at understanding the ever-changing and complex healthcare market and helping clients solve issues. Learn about the payer challenges, potential reimbursements, and the competition to consider.